Expression levels of tumor necrosis factor‑α and the corresponding receptors are correlated with trauma severity

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2747-2751

  Liu, Chang ^a   Tang, Jianwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

p55; p75; Patient; Trauma; Tumor necrosis factor receptor 1; Tumor necrosis factor receptor 2; Tumor necrosis factor receptors; Tumor necrosis factor

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INJURY; INJURY SCALE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION;

EID: 84908020729     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2575     Document Type: Article

References (35)

1. Lenz A, Franklin GA and Cheadle WG: Systemic inflammation after trauma. Injury 38: 1336-1345, 2007.
2. Esposito E and Cuzzocrea S: TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 16: 3152-3167, 2009.
3. Woodcock T and Morganti-Kossmann MC: The role of markers of inflammation in traumatic brain injury. Front Neurol 4: 18, 2013.
4. Vandenabeele P, Declercq W, Beyaert R and Fiers W: Two tumour necrosis factor receptors: structure and function. Trends Cell Biol, 5, 392-399, 1995.
5. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H and Lesslauer W: Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61: 351-359, 1990.
6. Smith CA, Davis T, Anderson D, et al: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019-1023, 1990.
7. Goodwin RG, Anderson D, Jerzy R, et al: Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol Cell Biol 11, 3020-3026: 1991.
8. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr and Goeddel DV: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88: 9292-9296, 1991.
9. Choi SJ, Lee KH, Park HS, Kim SK, Koh CM and Park JY: Differential expression, shedding, cytokine regulation and function of TNFR1 and TNFR2 in human fetal astrocytes. Yonsei Med J 46: 818-826, 2005.
10. Cinat M, Waxman K, Vaziri ND, Daughters K, Yousefi S, Scannell G and Tominaga GT: Soluble cytokine receptors and receptor antagonists are sequentially released after trauma. J Trauma 39: 112-120, 1995.
11. Ertel W, Keel M, Bonaccio M, Steckholzer U, Gallati H, Kenney JS and Trentz O: Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma 39: 879-887, 1995.
12. Stein DM, Lindell A, Murdock KR, et al: Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma 70: 1096-1103, 2011.
13. Dalgard CL, Cole JT, Kean WS, et al: The cytokine temporal profile in rat cortex after controlled cortical impact. Front Mol Neurosci 5: 6, 2012.
14. Hoch RC, Rodriguez R, Manning T, Bishop M, Mead P, Shoemaker WC and Abraham E: Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med 21: 839-845, 1993.
15. Rabinovici R, John R, Esser KM, Vernick J and Feuerstein G: Serum tumor necrosis factor-alpha profile in trauma patients. J Trauma 35: 698-702, 1993.
16. Tan LR, Waxman K, Scannell G, Ioli G and Granger GA: Trauma causes early release of soluble receptors for tumor necrosis factor. J Trauma 34: 634-638, 1993.
17. Cinat ME, Waxman K, Granger GA, Pearce W, Annas C and Daughters K: Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J Am Coll Surg 179: 529-537, 1994.
18. Svoboda P, Kantorová I and Ochmann J: Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma 36: 336-340, 1994.
19. Majetschak M, Flach R, Heukamp T, et al: Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma 43: 880-887, 1997.
20. Spielmann S, Kerner T, Ahlers O, Keh D, Gerlach M and Gerlach H: Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand 45: 364-370, 2001.
21. Zerey M, Burns JM, Kercher KW, Kuwada TS and Heniford BT: Minimally invasive management of colon cancer. Surg Innov 13: 5-15, 2006.
22. Feldman AM: TNF alpha - still a therapeutic target. Clin Transl Sci 1: 145, 2008.
23. Kawasaki Y, Zhang L, Cheng JK and Ji RR: Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 28: 5189-5194, 2008.
24. Oshima T, Lee S, Sato A, Oda S, Hirasawa H and Yamashita T: TNF-alpha contributes to axonal sprouting and functional recovery following traumatic brain injury. Brain Res 1290: 102-110, 2009.
25. Spinas GA, Keller U and Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533-536, 1992.
26. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL and Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA, 89: 4845-4849, 1992.
27. Gerlach H, Gerlach M and Clauss M: Relevance of tumour necrosis factor-alpha and interleukin-1-alpha in the pathogenesis of hypoxia-related organ failure. Eur J Anaesthesiol 10: 273-285, 1993.
28. Rogy MA, Coyle SM, Oldenburg HS, et al: Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178: 132-138, 1994.
29. Pellegrini JD, Puyana JC, Lapchak PH, Kodys K and Miller-Graziano CL: A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 6: 389-396, 1996.
30. Froon AH, Bemelmans MH, Greve JW, van der Linden CJ and Buurman WA: Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 22: 803-809, 1994.
31. Balk RA: Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 16: 337-352, 2000.
32. Esposito E and Cuzzocrea S: Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 32: 107-115, 2011.
33. Chio CC, Chang CH, Wang CC, et al: Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α. BMC Neurosci 14: 33, 2013.
34. Shuh M, Bohorquez H, Loss GE Jr and Cohen AJ: Tumor necrosis factor-α: life and death of hepatocytes during liver ischemia/reperfusion injury. Ochsner J 13: 119-130, 2013.
35. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H and DePuy V: Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 26: 1051-1070, 2012.